Cell killing by antibody-drug conjugates
- PMID: 17553616
- DOI: 10.1016/j.canlet.2007.04.010
Cell killing by antibody-drug conjugates
Abstract
Antibody-drug conjugates (ADCs) are designed to specifically bind to and kill cells expressing their target antigens. In addition to the obvious requirement of the presence of the target antigen on the cell surface, several other factors contribute to the sensitivity of target cells to the action of ADCs. These include (i) the rate of internalization of the ADC, (ii) its proteolytic degradation in late endosomes and lysosomes and the subsequent release of cytotoxic drug, and (iii) the intracellular concentration of the released drug. In addition to killing antigen-expressing cells, some ADCs were found to kill bystander cells irrespective of their antigen expression. This review summarizes the current knowledge of the mechanisms of killing of antigen-expressing and bystander cells by antibody-drug conjugates.
Similar articles
-
Quantitative characterization of in vitro bystander effect of antibody-drug conjugates.J Pharmacokinet Pharmacodyn. 2016 Dec;43(6):567-582. doi: 10.1007/s10928-016-9495-8. Epub 2016 Sep 26. J Pharmacokinet Pharmacodyn. 2016. PMID: 27670282 Free PMC article.
-
Intracellular Released Payload Influences Potency and Bystander-Killing Effects of Antibody-Drug Conjugates in Preclinical Models.Cancer Res. 2016 May 1;76(9):2710-9. doi: 10.1158/0008-5472.CAN-15-1795. Epub 2016 Feb 26. Cancer Res. 2016. PMID: 26921341
-
Targeted cancer therapy: conferring specificity to cytotoxic drugs.Acc Chem Res. 2008 Jan;41(1):98-107. doi: 10.1021/ar700108g. Epub 2007 Aug 18. Acc Chem Res. 2008. PMID: 17705444 Review.
-
Selecting an optimal antibody for antibody-drug conjugate therapy: internalization and intracellular localization.Methods Mol Biol. 2013;1045:41-9. doi: 10.1007/978-1-62703-541-5_3. Methods Mol Biol. 2013. PMID: 23913140
-
Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?Br J Cancer. 2017 Dec 5;117(12):1736-1742. doi: 10.1038/bjc.2017.367. Epub 2017 Oct 24. Br J Cancer. 2017. PMID: 29065110 Free PMC article. Review.
Cited by
-
Antibody-Drug Conjugates-A Tutorial Review.Molecules. 2021 May 15;26(10):2943. doi: 10.3390/molecules26102943. Molecules. 2021. PMID: 34063364 Free PMC article. Review.
-
Optimising the delivery of tubulin targeting agents through antibody conjugation.Pharm Res. 2012 Nov;29(11):2972-84. doi: 10.1007/s11095-012-0810-9. Epub 2012 Jul 10. Pharm Res. 2012. PMID: 22777294 Review.
-
Large-scale site-specific mapping of the O-GalNAc glycoproteome.Nat Protoc. 2020 Aug;15(8):2589-2610. doi: 10.1038/s41596-020-0345-1. Epub 2020 Jul 17. Nat Protoc. 2020. PMID: 32681153 Free PMC article.
-
An Elaborate New Linker System Significantly Enhances the Efficacy of an HER2-Antibody-Drug Conjugate against Refractory HER2-Positive Cancers.Adv Sci (Weinh). 2021 Dec;8(23):e2102414. doi: 10.1002/advs.202102414. Epub 2021 Oct 18. Adv Sci (Weinh). 2021. PMID: 34664433 Free PMC article. Clinical Trial.
-
Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumab-resistant breast cancer cells in vivo.Breast Cancer Res. 2011 Apr 21;13(2):R46. doi: 10.1186/bcr2868. Breast Cancer Res. 2011. PMID: 21510863 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources